高级检索
王四全, 张迟, 王雷, 赵明江. 2015 — 2017年湖北省脊髓灰质炎疫苗疑似预防接种异常反应监测分析[J]. 中国公共卫生, 2018, 34(5): 736-740. DOI: 10.11847/zgggws1118771
引用本文: 王四全, 张迟, 王雷, 赵明江. 2015 — 2017年湖北省脊髓灰质炎疫苗疑似预防接种异常反应监测分析[J]. 中国公共卫生, 2018, 34(5): 736-740. DOI: 10.11847/zgggws1118771
Si-quan WANG, Chi ZHANG, Lei WANG, . Suspected adverse events following immunization of poliomyelitis vaccines in Hubei province: analysis on surveillance data of 2015 – 2017[J]. Chinese Journal of Public Health, 2018, 34(5): 736-740. DOI: 10.11847/zgggws1118771
Citation: Si-quan WANG, Chi ZHANG, Lei WANG, . Suspected adverse events following immunization of poliomyelitis vaccines in Hubei province: analysis on surveillance data of 2015 – 2017[J]. Chinese Journal of Public Health, 2018, 34(5): 736-740. DOI: 10.11847/zgggws1118771

2015 — 2017年湖北省脊髓灰质炎疫苗疑似预防接种异常反应监测分析

Suspected adverse events following immunization of poliomyelitis vaccines in Hubei province: analysis on surveillance data of 2015 – 2017

  • 摘要:
      目的  比较分析2015 — 2017年湖北省脊髓灰质炎(脊灰)疫苗接种后疑似预防接种异常反应(AEFI)的发生特征,评价脊灰疫苗安全性。
      方法  采用描述流行病学方法对湖北省2015 — 2017年AEFI信息管理系统三价脊灰减毒活疫苗(TtOPV)、Salk株脊灰灭活疫苗(IPV-Salk)、Sabin株脊灰灭活疫苗(IPV-Sabin)、二价脊灰减毒活疫苗 (bOPV) AEFI个案数据进行统计分析。
      结果  湖北省2015 — 2017年tOPV、bOPV、IPV-Salk 、IPV-Sabin接种后AEFI报告发生率4.78/10万剂~26.94/10万剂。4种脊灰疫苗接种后AEFI中,一般反应均占80 %以上,异常反应占11.6 %~20.56 %,男童均多于女童,发生年龄均以 < 1岁组为主,90 %以上AEFI发生在接种后≤1 d。脊灰减毒活疫苗第1剂次AEFI发生率明显高于后续剂次,脊灰灭活疫苗各接种剂次间AEFI发生率无差异。新上市的bOPV和IPV-Sabin AEFI发生率分别高于tOPV和IPV-Salk,但多以一般反应和过敏性皮疹为主。
      结论  湖北省脊灰疫苗安全性良好,但仍需关注罕见异常反应病例的发生。

     

    Abstract:
      Objective  To analyze occurrence features of adverse events following immunization (AEFI) of poliomyelitis vaccines in Hubei province from 2015 to 2017, and to evaluate the safety of the vaccines.
      Methods  We collected reported AEFI cases related to vaccinations of trivalent oral poliomyelitis attenuated live vaccine (tOPV), inactivated poliomyelitis vaccine made from Salk strains (IPV-Salk), inactivated poliomyelitis vaccine made from sabin strains (IPV-Sabin), and bivalent oral poliomyelitis attenuated live vaccine (bOPV) in Hubei province from 2015 to 2017 via AEFI information management system; then we analyzed the data with descriptive epidemiology method.
      Results  During the 3-year period, the incidence rates of AEFI related to vaccinations of tOPV, bOPV, IPV-Salk, and IPV-Sabin ranged between 4.78 per 100 000 doses to 26.94 per 100 000 doses. Of all the AEFI reported, 80% were common reactions and 11.6% – 20.56% were rare reactions. Most of the reported AEFI cases were the small children less than one years old and the male cases was more than the female cases. More than 90% of the reported cases occurred within one day after the vaccination. For the AEFI cases related to the vaccinations of bOPV and tOPV, the incidence rate of first dose was higher than that of follow-up dose, but there was no obvious difference in the incidence rate for the vaccinations of IPV-Salk and IPV-Sabin. The AEFI incidence rate related to the newly listed bOPV and IPV-Sabin was higher than that related to OPV and IPV-Salk but main reactions of the newly listed vaccines were common vaccine reactions and allergic rash.
      Conclusion  The vaccination of poliomyelitis vaccines is highly safe but the surveillance on rare reactions of the vaccination remains to be done.

     

/

返回文章
返回